SCHEMBL25816385

SCHEMBL25816385

CC(C)(C)OC(=O)NOCCC(O)c1cncc(Br)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 9/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDM4E B2RXH2 1/20 0.35
RORC P51449 1/20 0.35
LCK P06239 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32
IDO1 P14902 1/20 0.31
NPC1 O15118 1/20 0.31
RECQL P46063 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
LMNA P02545 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30678226 0.81 AAK1 (0.35) AAK1NPC1RECQLRAB9ASMN1; SMN2
SCHEMBL24726412 0.81 AAK1 (0.35) AAK1NPC1RECQLRAB9ASMN1; SMN2
SCHEMBL21783498 0.77 ADRB1 (0.34) AAK1
SCHEMBL22456387 0.76 RIPK1 (0.50) NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL22232743 0.76 RIPK1 (0.50) NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL18921533 0.76 RIPK1 (0.50) NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL28873146 0.74 FOLH1 (0.34) AAK1
SCHEMBL18921432 0.74 CTSS (0.40) LMNA
SCHEMBL1419503 0.74 CTSK (0.41) AAK1CYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL31226755 0.74 AAK1 (0.39) AAK1CYP1A2CYP3A4CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 AAK1 27/4885CYP1A2 1540/4885CYP3A4 2392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.